Perrigo Co. plc's active pharmaceutical ingredients business was renamed to Wavelength Pharmaceuticals after U.S. private investment firm SK Capital completed the acquisition.

Wavelength produces generic active pharmaceutical ingredients, with primary operations in Israel and supporting functions in the U.S. and India.

Apollo Global Management and its affiliates along with MidCap Financial provided debt financing for the transaction. RBC Capital Markets LLC and Rothschild acted as SK Capital's joint advisers.